Summary Inactivation of the p53 tumour-suppressor gene is common in a wide variety of human neoplasms. In 
Colorectal cancer is the second most prevalent cancer in the Western world (Boring et al., 1991) . Recent studies have elucidated several genetic changes associated with this type of cancer. Activating point mutations in ras oncogenes are common in colorectal cancer and are typically found in more than 50% of tumours, whereas loss of heterozygosity (LOH) is frequently found at 5q (APC), 17p (p53), and 18q (DCC) (Vogelstein et al., 1988) . According to Knudson's model of suppressor-gene function, such losses are thought to reveal inactivating mutations in the target genes within such regions (Knudson, 1971) .
Alterations in the p53 tumour-suppressor gene are among the most frequently encountered genetic aberrations in human malignancies (Hollstein et al., 1991) , which suggests a central role for the p53 protein in human carcinogenesis. The wild-type p53 protein suppresses tumour cell growth, binds to specific DNA sequences and participates in cell-cycle regulation (for review see Levine, 1992; Kern, 1994) . Inactivating mutations in the p53 tumour-suppressor gene are very frequent in human colorectal carcinomas and are usually accompanied by loss of the remaining wild-type copy of the gene (Baker et al., 1989 (Baker et al., , 1990 Campo et al., 1991; Cunningham et al., 1992) . As early studies indicated that the vast majority of p53 gene mutations are located in exons 5-8, mutational analyses were principally confined to these exons. In addition, not all sequence alterations that lead to an amino acid change in the p53 protein result in impaired p53 function. Examples include temperature-sensitive forms of p53 (Halevy et al., 1990) and mutations that apparently have limited activity in assays for p53 function (Frebourg et al., 1992; Srivastava et al., 1993) . For these reasons, mutational analysis of the p53 gene will only reveal a subset of tumours with p53 dysfunction.
A second method for the detection of p53 inactivation is based on the fact that the majority of inactivating mutations in p53 lead to an increased half-life of the p53 protein.
Although p53 protein levels in cells with wild-type p53 are too low to detect by routine immunohistochemistry, most p53 gene mutations lead to the accumulation of p53 protein, which is easily detectable with this technique (van den Berg et al., 1989) . Because of the relative ease of this approach, a large number of studies have investigated alterations in p53 using immunohistochemistry (Campo et al., 1991; Cunningham et al., 1992; Kaklamanis et al., 1993; Auvinen et al., 1994; Scott et al., 1991; Starzynska et al., 1992; Bell et al., 1993) . In some reports these findings were accompanied by a mutational a'nalysis of exons 5 -8 of the p53 gene (Cunningham et al., 1992; Cripps et al., 1994) . However, the comparison of the results obtained with these studies is often difficult because of the use of different antibodies and experimental conditions that greatly,influence the number of p53-positive cells (Baas et al., 1994) . It has also been reported that not all inactivating point mutations in p53 lead to protein accumulation detectable by IHC (Rodrigues et al., 1990) . In addition, mutations resulting in a truncated p53 protein, such as frame-shift or nonsense mutations, will not yield detectable p53 protein and thus give a false-negative result when only immunohistochemical detection methods are used.
Recently, a gene that can be activated by wild-type p53 was described, WAFI/Cipi (El-Deiry et al., 1993; Harper et al., 1993 al., 1988) . Exons 5 -8 were amplified separately by polymerase chain reaction (PCR) using primers and conditions as described elsewhere (DiGiuseppe et al., 1994) . Mutations in the p53 gene were identified by analysing the PCR products by denaturing gradient gel electrophoresis (DGGE) as described previously (DiGiuseppe et al., 1994; Hamelin et al., 1993 (Baas et al., 1995; Kessis et al., 1993) .
Immunohistochemistry for p53 and p21 WAFI/cipl Immunohistochemistry for p53 was performed in all 46 colorectal carcinomas with the antibody D07 (Dakopatts, Glostrup, Denmark) as described previously (Baas et al., 1994) . p2lWAFI/CiPl protein was detected with antibody Ab-I for WAFI (Oncogene Science, Cambridge, MA) using citrate buffer for antigen enhancement (Baas et al., 1994) , with final detection through standard avidin-biotin staining methods. Slides were scored independently by two observers (GJAO and IOB) and categorised into two groups: no expression (less than 10% positive tumour cells) and positive expression (more than 10% staining tumour cells) (Cunningham et al., 1992; Kaklamanis et al., 1993; Cripps et al., 1994) .
Statistical analysis Differences in frequencies were evaluated by two-sided Fisher's exact test or by x2 test for trend. P-values less than 0.05 were considered statistically significant. For a multivariate survival analysis, Kaplan-Meier curves were plotted for p53 mutation only, p53 IHC and p21WAFl/ciPl IHC. In an attempt to compensate for the shortcomings of the assays for p53 status, tumours were also categorised into two groups based upon the number of alteration as measured by the three p53 assays (LOH at 17p, p53 IHC and p53 gene mutation). When two or more of these assays showed alterations in p53, inactivation of the p53 tumour suppressor was considered to be present, whereas the remainder of the tumours were considered to be wild type for p53. A multivariate survival analysis based upon this classification was performed for the total group of tumours, but also for Dukes' B and C cases only, to minimise confounding by stage. Statistical significance of the survival difference was tested by log-rank. (Table I) . From this sample eight individual plasmid clones were analysed to determine the origin of these two mutations. One of the resulting clones had the wild-type exon 8, while the other seven contained both mutations, indicating that both mutations were originally present in the same p53 allele. Sample number 41 also had multiple mutations: a three-nucleotide deletion in exon 6 that deleted one of two prolines, and two different mutations in exon 5, one in codon 168 (CAC-+TAC, histidine to tyrosine) and one in codon 174 that did not result in an amino acid change (AGG-+AGA, arginine). Clonal analysis of seven individual plasmid clones showed that the two exon 5 mutations occurred in different DNA strands: the codon 168 mutation was found in one clone, and the codon 174 mutation was found in three clones. The remaining four clones were wild type. Two additional samples harboured gene mutations that did not alter the protein-encoding sequence. Sample number 6 was mutated at codon 217 (GTG-)GTA, valine) and sample number 48 had a mutation at codon 197 (GTG-+GTA, valine).
To further assess the p53 status of the colorectal carcinomas, the samples were also analysed for p53 protein accumulation using immunohistochemistry. In this analysis 21 samples showed positive nuclear staining for p53 (46%) ( (Table IV) (Table III) . No difference was observed between the p2lWAFI/Cipl IHCnegative and IHC-positive groups when compared with FAL, DNA ploidy and LOH at Sq, 17p, or 1 8q (Table  IV) . There was also no difference in survival between the p2lWAFI/CiPl_negative and -positive group, although the p2lWAFI/CiPl_positive group appeared to have a slightly better survival than the p2lWAFI/CiPl_negative group (Figure 2b) .
Expression of p21WAFI/Cipl was also found in the crypt epithelium of normal, non-neoplastic colorectal mucosa. Typically, epithelial cells lining the lower two-thirds of the crypts, where proliferation takes place, were negative for p21WAFI/CipI immunohistochemical staining. Positivity for p21WAFI/CiPl was a consistent finding in the upper one-third of the crypts and the surface epithelium, outside the progenitor zone but where terminally differentiating crypt cells are found. Staining for p53 was always negative in nonneoplastic crypt epithelium.
Discussion
In this study we investigated the clinical significance of the p53/WAFl pathway in colorectal cancer. The study group consisted of 46 carcinomas that were previously investigated for loss of heterozygosity at 5q, 17p and 18q (Kern et al., 1989 ), activating point mutations in ras oncogenes (Kern et al., 1989) and DNA ploidy al., 1993; DiGiuseppe et al., 1994) . In our study group, 19 of the 46 colorectal carcinomas (41%) showed inactivating mutations in the p53 gene. This frequency is lower than, but not significantly different from, those reported in the literature (Rodrigues et al., 1990; Lothe et al., 1992; Hamelin et al., 1994) . Mutational 'hotspots' for p53 have been defined in previous studies. About one-third of all mutations in colorectal cancer occur in codons 175, 248 or 273. In the present study 5 out of the 19 p53 mutation-positive cases (26%) were mutated in one of these three codons, whereas mutations in other codons that are frequently altered in human neoplasms (codons 179, 196, 220, 245) were also found. The two mutations found in sample number 71 (codons 262 and 269) have not been reported previously. Detailed analysis of these mutations revealed that they were present in the same allele of p53. In contrast, two mutations in case number 41 were present in different alleles. Multiple mutations in one tumour sample have been reported previously (Baker et al., 1990; Hamelin et al., 1994) , but their biological significance remains uncertain.
Although DNA sequence analysis of exons 5-8 will detect the majority of the mutations, inactivating mutations in other exons, promoter sequences or positions affecting mRNA splicing may still be present. When such mutations lead to accumulation of p53 protein, detecting by immunohistochemistry will yield more accurate results than DNA sequence analysis. Several immunohistochemical studies have investigated the inactivation of p53. In some of these studies, a positive p53 IHC was associated with shortened survival (Starzynska et al., 1992; Auvinen et al., 1994) , although the effect was weak or absent in others (Scott et al., 1991; Bell et al., 1993) . We have previously reported a similar study in which we did not find an association between p53 IHC and survival (Mulder et al., 1995) . In all these studies, the methods used to detect p53 protein were similar, although different antibodies for p53 were employed. From our own experience, the choice of antibody can greatly influence the number of cases that show positive staining (Baas et al., 1994) , and the use of antigen retrieval procedures may lead to an overestimation of the number of p53-positive cases (Baas et al., 1996) . LOH at 17p is also associated with p53 mutations (Baker et al., 1990) . In one study, p53 gene mutations correlated with shortened survival, 17p allelic loss, location of the tumour and 5q and 18q LOH (Hamelin et al., 1994) . Although our study group was limited, a strong association between p53 and 17p LOH was also found, but we did not find any of the other associations. When only p53 sequence mutations were considered, inactivation of p53 appeared to predict a poorer prognosis, although the difference did not reach statistical significance. Of note, in the Dukes' B and C tumours, where a prognostic marker may prove most valuable in clinical management, the differences were not statistically significant, but our study group was small. One of the main downstream effector molecules of p53 is p2IW"CI'P, a cyclin-dependent kinase inhibitor. Induction of p21wAl' p is directly dependent on wild-type p53 protein accumulation, such as occurs after the induction of sublethal DNA damage (El-Deiry et al., 1993) . Thus, activation of p21W"-l' cP may reflect p53 status of tumour cells. However, when p53 status was compared with p2IWIF' cipI protein expression no obvious association between the two parameters was found. This finding is in agreement with recently published data, showing that a direct relationship between protein expression of p53 and p2lW"I'l9 is only observed after sublethal DNA damage, but not under normal conditions (El-Deiry et al., 1995; DiGiuseppe et al., 1995) . We observed no association of p2lw"l CPJ IHC with any of the clinical and pathological parameters, a finding that would limit the use of p21W-FI sP' IHC as a specific tumour marker, or as a marker for cancer survival. Recently, p53-independent, celltype specific pathways leading to the induction of p2lW"l CiPl have been reported (Michiele et al., 1994; Halevy et al., 1995) . Increased levels of p2lWAF'Icapl may not only lead to cell cycle arrest after p53 protein accumulation but may also be linked with terminal differentiation of specialised cells (Parker et al., 1995) .
Indeed, the highest levels of p2lw"l'Pl were found in terminally differentiated colonic crypt cells in non-neoplastic mucosa (El-Deiry et al., 1995) , as in our study. The observed pattern of p2 lw'AFcP expression compares well with the mutually exclusive relationship between proliferation and differentiation typical in many different nonneoplastic tissue types, including colonic epithelium.
This study indicates that high p2lWAF''ciP' protein levels are not unique to tumour cells with intact p53 function. In colorectal carcinomas with a mutated p53 gene, cells positive for p21w"'IP' staining probably harbour a functioning differentiation pathway activated through a p53-independent mechanism. Specimens positive for p21w /'cl showed a heterogeneous staining pattern for p2lwAJ"'iPI, but the signia of this finding is unclear. The p53 mutational status in colorectal carcinoma cells is not reflected by the levels of p2lw"I'P protein. Our study thus demonstrates that the induction of p21w"'IP' itself through p53-independent mechanisms may occur in a significant fraction of colorectal tumours.
